Mirava Bio is the European Operating Partner for innovative biotech and pharma companies with no commercial footprint in Europe. It was built by operators who have launched category-defining rare disease and gene therapies across Europe — and know exactly what it takes to do it de-risked, capital-efficient, and fully in your control.
Vincent Lévêque is a seasoned biopharma executive with over 20 years of experience leading commercial expansion for rare-disease and advanced therapy (ATMP) launches across Europe, the Middle East, and Eurasia. He has built international commercial footprints for U.S.-based biotechs and successfully led EMEE launches of landmark therapies such as Zolgensma (Novartis) and Soliris (Alexion). Before founding Mirava Bio, Vincent served as Global General Manager and VP at Kiniksa Pharmaceuticals and as VP of Marketing & Commercial Operations at Novartis Gene Therapies. A passionate, people-driven leader, he is known for building high-performing teams and executing disciplined, cross-functional go-to-market strategies in complex markets. Fluent in English, French, Spanish, and Portuguese, Vincent brings both global perspective and deep local expertise to every project.
LinkedIn ↗Every company, product, and team has its own profile, journey, and priorities — just as every patient is unique. Let’s connect to discuss the right path to reaching EMEE patients.